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Abstract
Due to the sensitivity of location, brain cancer is one of the most difficult and deadly known cancers. There are various forms of 
cancer in the brain with many shared characteristics as well as unique manifestations in each. While cancers originating in the 
central nervous system present in several ways, the most common forms are high grade gliomas generally, and glioblastoma or 
anaplastic astrocytomas specifically. With the advent of technology, researchers have been able to propose and refine extensive 
profiles of these relentless tumors, enabling greater and more successful treatment profiles to be developed. Where treatments 
used to consist primarily of chemotherapy and surgery, research has enabled the development of immunotherapy and gene 
therapy techniques as well as alternative treatments to take on the caustic disease.
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Introduction
The foremost distinction of brain tumors is between primary; 
those that originated within the brain itself, and secondary; those 
that developed beyond the blood brain barrier and migrated to 
the brain under metastatic conditions. Secondary tumors ac-
count for the majority of all brain cancers and approximately 
50% of these tumors metastasize from lung cancers (Gallego, 
2015). According to the 2014 World Cancer Report, patients 
diagnosed with glioblastomas were measured to have a median 
survival time of 12-15 months post diagnosis with fewer than 
5% of patients living beyond 3 years (Patchell, 2003).Under the 
World Health Organization’s grading protocol for central ner-
vous system (CNS) cancers, glioblastomas (GBM) are a grade 
IV glioma (Bleeker, et al., 2011). This is the most common form 
of primary brain tumor and the most fatal found in humans, 
accounting for 15% of all intracranial neoplasms (Bleeker, et al., 
2011; Young, et al., 2015). The average age at diagnosis is 64 years 
old and the approximate annual incidence of GBM per 100,000 
population is 3.19 cases, making an understanding of the dis-
ease and its treatment of paramount importance (Ostrom et 
al., 2017). GBMs develop rapidly de novo in astrocytes, star-
shaped neuroglial cells suspected to play a role in blood brain 
barrier maintenance and neurotransmitter management (Kolb 
& Whishaw, 2009). This swift development occurs without any 
previous primary or lower grade lesion development that may 
indicate or preclude the GBM onset, making early diagnosis and 
adequate treatment more difficult. 
Since 2005, the first-line standard of care has been estab-
lished as surgery followed by chemotherapy, most often with 
temozolomide (TMZ), and radiotherapy. Despite the established 
longevity of this standard, its efficacy is highly questionable and 
there is still recurrence in the majority of cases (Patchell, 2003). 
To complicate matters further, there is no second-line standard 
of care for glioblastomas and recurrence is consistently fatal 
(Roy, et al., 2015).
Discussion: Difficulties with Conventional 
Treatments
One of the significant factors contributing to the aggressive 
character of GBMs is their infiltrative nature. Astrocytes have 
extensive networks of processes forming from their cell bodies, 
creating an intricately branched structure extending through-
out the nervous system. Where some cancers merely invade 
their host tissue, the cells of grade IV astrocytomas penetrate 
their host with protrusions. These processes weave a complex 
margin with host tissue that blurs the border between invasive 
and host cells. This makes complete surgical resection nearly 
impossible as practitioners are unable to differentiate between, 
and separate, the healthy and malignant tissue. As a result, re-
currence is extremely high in GBMs and alternative treatments 
must often be considered post-surgery when complete resec-
tion is not achieved (Patchell, 2003). 
Beyond the inability to properly remove gliomas, the benefit 
of surgery is questionable. In a study of recurrent brain tumors, 
researchers found no significant benefit to a second resection, 
though a first resection did confer an increased overall survival 
(Suchorska et al., 2015). Nonetheless, the nature of the neurosur-
gical procedure lends itself to various complications. Along with 
the wound and postsurgical medical complications, brain surgery 
runs the risk of systemic and cortical injuries, damaging physical 
and mental health with the most common risk of neurological 
impairment (Jackson, et al., 2016). Research also found that the 
acquisition of motor and language deficits post-surgery is linked 
to decreased survival rates compared to patients without surgical 
brain damage (McGirt et al., 2009). The results of these studies 
indicate that the benefit of surgery is questionable.
Chemotherapy treatments generally follow the attempted re-
section procedures but have limited success due to the imperme-
ability of the blood brain barrier to foreign chemicals (Deeken & 
Loscher, 2007). TMZ is a common chemotherapy drug for gliomas 
and has demonstrated mild success against GBM and anaplastic 
astrocytoma but its overall effectiveness is slim and is accom-
panied by a cocktail of undesirable side effects (Friedman, et al, 
2000). The established first-line standard of care is precarious and 
insufficient. As a result, research has turned to alternative meth-
ods by which to treat and manage this deadly.
Genetic Analysis
In order to purposefully theorize and discuss possible solutions 
and treatments, GBM manifestation must first be understood. 
Occurring primarily in older patients, GBM progresses quickly 
and with low survival rates. A minority of cases have been seen in 
younger patients with a history of epilepsy connected to progres-
sive low-grade gliomas (Ostrom et al., 2015). To address the lack 
of understanding, research continues to look for commonalities 
in tumor onset. As genomic instability is an enabling characteristic 
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of cancer, efforts have been made in the field to source a prima-
ry effector with genetic basis. As of yet, there is only one con-
firmed molecular predictive factor for GBM - methylation of the 
O6-methylguanine-DNA methyltransferase (MGMT) promoter 
(Bleeker, et al, 2011). The relative dearth of information on the 
molecular basis for GBM requires additional research. 
Whole-genome single nucleotide polymorphism (SNP)-based 
array analysis of gene expression in GBM patients has indicated 
several genetic changes that shed some light on the nature of 
the illness. Notably, loss of heterozygosity frequently occurs on 
the 17p gene, which contains the tumor protein 53 (p53) (The 
Cancer Genome Atlas (TCGA), Research Network, 2008). Loss 
of heterozygosity refers to the deletion of a chromosome por-
tion with the corresponding homologous segment being dupli-
cated to compensate for the loss of gene neutrality (Bleeker, et 
al, 2011). The significance of this mutation is reflected in the loss 
of genetic code for p53.   p53 encodes a nuclear phosphopro-
tein involved in regulation of cell proliferation. In other words, 
wild type p53 is a tumor suppressor gene. Mutations in p53 not 
only cause loss of tumor suppression, they can activate p53 to 
an oncogene in a negatively dominant fashion implicating these 
mutations in a number of cancers (Finlay, et al., 1989). Further, 
loss of heterozygosity of chromosome 10q is associated with 
poor rates of survival and is the most common genetic alter-
ation found in primary and secondary GBM’s. This chromosome 
contains various tumor suppression codes, most notably the 
region containing ANXA7, an epidermal growth factor recep-
tor (EGFR) inhibitor, and deletions contribute to a proliferation 
of cell growth; a distinguishing behavior of cancerous tumors 
(Yadav et al., 2009). 
Additional research focuses on genetic amplifications associ-
ated with GBM. Specifically, amplification of the gene for EGFR 
on chromosome 7 has been shown to be a consistent charac-
teristic in glioblastomas (Finlay, et al, 1989; Bleeker, et al, 2011). 
Focal amplifications (amplifications containing a small concen-
tration of genes) correlate with overexpression or mutation 
of EGFR, leading to subsequent activation of the PI3K/AKT 
pathway, another indicator of poor prognosis (Beroukhim et al., 
2007; Phillips et al., 2006). General amplification of entire chro-
mosomes, specifically chromosome 7, has shown correlation 
with the activation of the Met axis, a codependent cycle with 
Hepatocyte Growth Factor (HGF) which furthers the occur-
rence of cell proliferation (The Cancer Genome Atlas (TCGA), 
Research Network, 2008). 
Another genetic component considers IDH1 mutations. 
The IDH1 gene codes for isocitrate dehydrogenase 1, a critical 
component of the citric acid cycle, catalyzing the conversion of 
isocitrate to α-ketoglutarate. Mutations of this gene have been 
discovered in 12% of glioblastomas (Watanabe, et al., 2008). 
Mutations of this enzyme do not appear to cause loss of func-
tion, rather, cancer-associated IDH1 mutations alter the reaction 
of the enzyme, enabling it to catalyze the NADPH-dependent 
reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). 
As many humans have a reduced capacity to dispose of 2HG 
in an efficient manner, overaccumulation of the metabolite has 
been implicated in the formation of malignant brain tumors 
(Dang et al., 2009). 2HG also has a penchant to activate NF-κB, 
a prominent protein complex that controls cytokine produc-
tion, cell survival, and DNA transcription, implicating it in many 
cancers, including various leukemias (Chen et al., 2016). 
Ultimately, the strongest evidence of a genetic aspect to GBM 
is that of the MGMT promoter. While TMZ treatment in general 
has shown some benefit, much of its effectiveness is diminished 
by this molecular occurrence. TMZ acts by modifying the O6-
position in guanines. This translates to DNA lesions leading to 
DNA cross-links preventing cell replication. MGMT can remove 
the alkyl groups and contribute to TMZ resistance but not 
when methylated. Because about 50% of patients exhibit MGMT 
methylation, the effectiveness of TMZ is considerably lessened 
in approximately half of all cases (Bleeker, et al., 2011). Research 
is being done particularly in this area to better understand the 
environment surrounding methylation and prospectively har-
nessing the power of methylation to increase TMZ effectiveness 
(Lee et al., 2018).
Additional aberrations in genetic behavior exist in GBM with 
varying degrees of frequency. With more tools becoming avail-
able, it is apparent that the picture of GBM is not clear and 
further genetic research is required. Nonetheless, these tools 
enable researchers to identify the most prevalent deviations 
from typical behavior. For example, many alterations occur 
within three primary pathways; the p53, RB, and PI3K/AKT 
pathways, and appear to occur in a mutually exclusive fashion 
(The Cancer Genome Atlas (TCGA), Research Network, 2008). 
This defines a narrower scope of application, hopefully resulting 
in the development of rational therapeutic techniques and drug 
design. These genomic approaches may ultimately contribute to 
more individualized therapies for greater patient longevity.
Immune Evasion and Immunotherapy
In addition to the complications involved with gene aberrations 
in malignant gliomas, the impressive rate at which GBMs evade 
natural immune response opens another point of study for 
prospective treatments. Avoidance of the immune system was 
added as a defining characteristic of cancer in 2011 and an ex-
amination of the natural immune response has helped develop 
vaccinations and treatments for various diseases (Hanahan & 
Weinberg, 2011). Nonetheless, the ability of tumors to dodge 
these receptors requires a better understanding, specifically in 
the brain. In line with original theories, the CNS is immuno-
logically privileged. Unfortunately, it is not quite as privileged 
as once suspected. While early theories assumed this privilege 
was a result of isolation of the brain by the blood brain barrier, 
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newer research refutes this. Peripheral immune cells do in fact 
cross the barrier, but CNS neurons and glia regulate immune 
responses in a different fashion than other cells (Carson, et 
al., 2006). Researchers have demonstrated this deviance from 
the standard immune system using experimental foreign grafts 
to rabbit brain. These grafts were rejected at a much slower 
rate than grafts to less unique locations (Medawar, 1948). An 
additional indication of CNS immune system inadequacy is the 
immune response of the brain in multiple sclerosis patients. The 
immune system of affected individuals appears to contribute 
directly to the proliferation of the disease rather than fighting it 
(Hemmer, et al., 2015). Despite these deficiencies, analysis sug-
gests proper manipulation of the immune system can assist in 
the fight against brain cancers, achieved through understanding 
the mechanism by which tumors evade it. 
ICT-107 is a multiple-antigen-pulsed dendritic cell vaccine 
containing multiple tumor-associated antigens (HER2, TRP-2, 
gp100, MAGE-1, IL13Rα2, and AIM-2) known to interact with 
glioma stem cells. These antigens may be ideal for vaccination 
as their introduction to the dendritic cell tumor environment 
stimulates T-cells to generate glioblastoma specific cytotoxicity 
(Huang et al., 2017). This immunotherapy was the first such trial 
to reflect significant results in terms of overall, progression-free 
survival in newly diagnosed GBM (McGranahan, et al., 2017). 
A phase III trial is awaiting additional funds to further investi-
gate the effectiveness of this vaccine (Phuphanich et al., 2012). 
Another vaccine in phase II trials is Gliovac. This vaccine utilizes 
autologous antigens from the patient subjects combined with 
allogeneic antigens (antigens with a dissimilar genetic makeup 
from that of the patient) derived from other GBM patients. 
Beyond using tumor lysate, the Gliovac vaccine is designed 
similarly to ICT-107 to encourage the development of cyto-
toxic T-cells to enhance the struggling immunological response 
(Schijns, Virgil E J C et al., 2015). Further studies examine the link 
between the CTLA-4 receptor, a constitutively active receptor 
on the Treg gene, and its downregulation of the immunologic 
response in active T cells (Leach, et al., 1996). By blocking CTLA-
4, researchers have seen considerable success with enhancing 
antitumor immunity, rejecting both artificially introduced and 
pre-established tumors. The rapid growth of immunothera-
peutic treatments stresses the importance of a more compre-
hensive understanding of the immune system and its reactions 
to foreign in vivo developments. More specific information on 
marker antibodies will go a long way in furthering treatments, 
not only for GBM but also for other immuno-evasive diseases.
Treatment with Infection
A seemingly counterproductive method of treatment has been 
considered to address incomplete resection of glioblastoma 
tumors. While the actual number of surgical site infections 
after malignant brain tumor resection is not well established, 
data indicates the rate to be about 3.4% (Uzuka et al., 2017). A 
speculative theory supported with anecdotal evidence present-
ed the idea that patients who developed postoperative bacterial 
infections and survived had a radically increased overall survival. 
A study reported four cases of patients with surgical site in-
fections living well beyond the expected range of survival for 
glioblastoma (Bowles, et al., 1999). This theory has been sub-
jected to several trials and though not statistically significant, re-
sults showed that many infected patients live longer on average 
though reverse logic may be cloud results. Infection may cor-
relate with increased life span because patients that live longer 
are more likely to develop an infection, not because infection 
lengthens survival (De Bonis et al., 2011).
Antiangiogenic Treatments
Antiangiogenic treatments have shown a lot of promise in can-
cers management and particularly in that of GBM as second-line 
treatments. The rationale for antiangiogenics is strong; as cancers 
are highly vascular, preventing the growth of blood vessels to sup-
ply the tumor should help deplete tumor resources and severely 
retard malignancy. Tumors are known to exploit the body’s nutri-
ent and oxygen supplies and require enhanced networks of blood 
and lymphatic vessels to facilitate this resource abuse (Nishida, 
et al., 2006). Vascular endothelial growth factor (VEGF) is a sig-
naling protein that stimulates the creation of blood vessels and 
has received increased attention as an indicator of oncogenesis 
(Pavlova & Thompson, 2016). To address this, researchers devel-
oped Bevacizumab, a monoclonal antibody that counters the 
effects of VEGF and has been approved for trials in the United 
States for some time. Dosed intravenously, Bevacizumab has been 
used independently as a monotherapy and in pairs or groups of 
antiangiogenics for a multi therapeutic approach in various cancer 
types. In early trials, a statistically significant number of patients 
demonstrated an improvement in overall survival, but random-
ized phase III trials have been unable to demonstrate an apprecia-
ble improvement in overall survival required to move this form of 
therapy forward (Bleeker, et al., 2011).
Retroviral Delivery
A promising treatment technique addresses issues with alterna-
tive treatments. Retroviral replicating viruses (RRVs), are a novel 
way of treatment delivery and contain a wide variety of unique 
characteristics that allow for highly specific gene transfer in an 
efficient manner. Pharmaceutical companies are combining many 
of the above therapies into a single, comprehensive treatment 
method for recurrent high-grade gliomas with the goal of ex-
tending these concepts to further treatments. 
Retroviruses are positive-sense RNA viruses. These obligate 
parasites cannot reproduce or complete their life cycle without 
a host cell. Once within a host, these viruses use the enzyme 
reverse transcriptase to produce DNA from the viral RNA 
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sequences. This DNA strand is then incorporated into the host 
cell genome with an integrase enzyme. By transferring it’s ge-
netic data into the host, the virus ensures it will be reproduced 
when the host reproduces. The applications of these viruses 
can allow scientists to produce desired proteins and genetic 
products for treatment purposes. These viruses confer many 
advantages to the treatment of cancers and in particular, of 
glioblastoma. One such benefit of RRVs is the selective accep-
tance within cells. It has previously been established that tumors 
exhibit a distinct loss of immunity and that a central aspect of 
cancer development is the evasion of the immune system. Cell 
populations naturally assess tissue to prevent proliferative, un-
controlled growth, and cancers evolve to avoid the anti-tumor 
response. This evolution evades immune checkpoints and reg-
ulators but also enables immunoediting, the process by which 
cancers read, react, and adapt to immune processes. By disabling 
the anti-tumor response, cancer cells can replicate continuously 
unchecked (Butt, et al., 2004). The lack of immunity that per-
mits cancers to exist also creates an opportunity for medical 
intervention. RRVs are generally recognized by healthy cells and 
dealt with accordingly by the normal immune system, but the 
reduced defense mechanism of cancer cells allows the RRV to 
incorporate genetic components into the cancer gene pool. This 
selective acceptance safeguards healthy tissue while priming 
cancer cells. Another key feature of RRVs is the ability to spread 
non-lytically and without an exceptional inflammatory response. 
Gene products are not produced until the virus is activated 
and this avoids an inflammatory response from the innate im-
mune system (which is not heavily compromised). Coupled 
with a nonlytic retroviral infection, this delivery system enables 
researchers to target specifically cancerous or immunocompro-
mised cells (Logg, et al., 2012).
The Tocagen therapy relies on an engineered retrovirus known 
as Toca 511 (vocimagene amiretrorepvec) for delivery. Toca 511 
is a murine leukemia virus that infects dividing cells, preferentially 
integrating into cells that are immune-deficient — in this case 
GBM cells. In addition, the retrovirus has no trouble crossing the 
blood brain barrier, an issue that arises with other treatments. 
The virus contains the genetic code for an altered cytosine 
deaminase (CD), a protein enzyme that catalyzes the reaction 
converting cytosine residues to uracil (Ostertag et al., 2011). In 
trials, after several cycles of RRV treatment, researchers found 
a high concentration of CD present in tumor cells, but none or 
insignificant levels expressed in quiescent cells. The retrovirus 
delivery method efficiently targets tumor cells and integrates its 
genetic contents into the DNA of the host cell without affecting 
the genetic integrity of healthy cells in the body.
While the success of the genetic transfer is significant, the 
expression of optimized CD within tumor cells is of little conse-
quence. Further action is required to have an impact on cancer-
ous cells. 5-fluorocytosine (5-FC) is subsequently administered 
as a prodrug, a drug in an inactive form. Despite widespread up-
take of 5-FC by the majority of cell types, this inactivity prevents 
any notable response from quiescent or typical cells. However, 
in the Toca-511 pretreated tumor cells, 5-FC is converted by 
CD to 5-fluorouracil (5-FU), a potent antineoplastic cancer 
drug used as the drug of choice for colorectal, esophageal, gas-
tric, and many other cancers. While the precise mechanism of 
5-FU is unknown, it is suspected to interfere with DNA syn-
thesis, protein synthesis, and RNA processing (Pinedo & Peters, 
1988). Collectively, these contribute to an incompatible state 
for the tumor cell leading to apoptosis and subsequent removal 
by the immune system. Furthermore, 5-FU has also been shown 
to destroy myeloid-derived suppressor cells. These cells help 
evade the immune system and elimination of these suppressor 
cells allows the patient’s natural immunity to assist in tumor 
destruction (Cloughesy et al., 2016). An additional advantage 
of the engineered 5-FU produced in Toca-511 allows the active 
drug to diffuse through the cell membrane, giving the potential 
to have therapeutic effects reaching beyond the cytosol of the 
parent cell (Hemmer, et al., 2015). There is strong evidence to 
suggest this phenomenon, called the bystander effect, occurred 
in preliminary trials and it resulted in an improved overall sur-
vival rate as well as an improved recurrence free outcome. The 
Tocagen drugs are undergoing clinical trials but the progress 
they signify in science is considerable and opens the door to a 
proliferation of improved treatment techniques.
Multi-Therapy
The multi hit model of cancer, also known as the Knudson hy-
pothesis, is the theory originally proposed in 1953 hypothesizing 
a stepwise component to oncogenesis. The theory suggests that 
cancer onset is not the result of a single mutation, rather the 
outcome of many mutations, creating conditions for the perfect 
storm that is cancer (Nordling, 1953). Knudson’s hypothesis 
has greater validity after “Hallmarks of Cancer” was published 
by Weinberg and Hanahan (Hanahan & Weinberg, 2000). The 
hallmarks reiterate the idea that cancer is multi-faceted and 
more complex than a single aberration in physiology and de-
velopment. The theory gives rise to an alternate approach to 
treatments; if the disease is multifaceted, then so must be the 
treatment plan. Various treatment proposals utilize this theo-
ry for multi-hit therapy. Some antiangiogenic treatments are 
being applied in conjunction with others for a comprehensive 
approach. Several attempts have been made, or are now in trials, 
that couple effective treatments like that of TMZ with newer 
medications to enhance their effectiveness. In concurrence with 
TMZ, patients have been tested with a wide variety of phar-
maceutical cocktails, including gefitinib and erlotinib, a pair of 
EGFR inhibitors (Bleeker, et al., 2011). Patients have also been 
treated with radiotherapy and Gliadel wafers. These wafers 
are intracranial implants containing carmustine, a nitrosourea 
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alkylating agent, and give a steady treatment of chemotherapy 
to their host after being inserted into the brain (van den Bent 
et al., 2008). Direct insertion prevents the need to circumvent 
the blood brain barrier and offers a continuous administration 
of the drug for the duration of the treatment. As a nitrosourea, 
carmustine alkylates DNA strands, preventing normal gene 
expression in cancer cells and dampening tumor development. 
Further, contrary to previous research, resistance to a single al-
kylating agent does not predict resistance to alternate alkylating 
agents, allowing for a multi-agent approach to prevent cancer 
gene expression (Schabel, 1976). 
The development of chimeric antigen receptor T-cell therapy 
(CAR-T) builds on the success of above-mentioned treatments 
such as retroviral genetic manipulation and immune system 
enhancement. This technique utilizes engineered T-cells to rec-
ognize specific markers in cancer cells and induce apoptosis. 
One lab at the Memorial Sloan Kettering Cancer Center fo-
cused on B cell acute lymphoblastic leukemia and is examin-
ing options to extend this therapy to gliomas. In the leukemia 
study, patients with relapsed B cell acute lymphoblastic leuke-
mia had T-cells isolated from plasma and treated with a vector. 
The vector programmed T-cells to produce chimeric antigen 
receptor, a receptor that can be engineered to enable the T 
cells to recognize specific proteins found in cancers (CD19 in 
this case) (Brentjens et al., 2013). One particular advantage of 
CAR-T therapy is the use of the patient’s own immune cells. 
Using autologous material decreases the incidence of rejection 
or other complications that frequently occur with the intro-
duction of foreign cells (Almasbak, et al., 2016). CAR-T therapy 
has demonstrated high rates of success with above an 88% long 
term survival rate and is being evaluated for expansion to a 
greater variety of cancers, including high- and low-grade glioma 
(Wilkins, Keeler, & Flotte, 2017).
The range of ideas employed with multi-hit therapies and 
techniques takes advantage of the advances made in genetic 
and molecular research. Introducing therapies that make use 
of immunotherapy and genetic recombination, or that address 
multiple facets of angiogenesis are particularly useful in tackling 
the multidimensional aspects of cancer. Combination treat-
ments allow scientists to develop a more comprehensive blend 
that can address the particular deficiencies associated with each 
individual medication and enable an extensive treatment plan 
for the greatest chances of survival.
Conclusion
Glioblastoma multiforme is a high-grade malignancy with a poor 
prognosis. While additional preventative research is required to 
improve diagnostic methods and screening, management meth-
ods are under rapid development to improve not only survival 
but also quality of life. A greater focus on intermolecular func-
tioning within GBM helps provide a better understanding of how 
to effectively diagnose and recognize the cancer. Additionally, 
such information allows the introduction of periodic screening 
in higher risk individuals as determined by these advances. By 
analyzing intermolecular pathways such as kinase receptors and 
genetic modifications, researchers can develop steps or proce-
dures to counter the cancer. This basic research extends itself 
heavily to the applied sector and allows for the creation of ther-
apies and treatments that respond to the characteristics and ac-
tions unique to this disease and the complexities of its location. 
Many treatments have already been proposed in an attempt 
to contain the rapid tumor proliferation associated with glio-
blastomas. With the knowledge gained from the success and 
failures of these treatments, adjusted multi-therapy approaches 
and novel replacement techniques have been developed. From 
genetics and immunological studies to bacterial and retroviral 
infections, these alternatives offer increased variability and pos-
sibility for patients. Despite the grim prognosis that typically 
accompanies the diagnosis of GBM, there is the potential for the 
cancer to no longer be as debilitating as it currently is or once 
was. Particularly through immunotherapy and gene therapy, as 
well as the use of antiangiogenics and nitrosourea alkylating 
agents, GBM can soon be combatted beyond the standard of 
surgical resection and chemotherapy.
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